{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-106919","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.310803+00:00","generated_at":"2026-05-29T05:42:39.166530+00:00","sec_items":["1.01","3.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"INmune Bio extends shareholder rights plan to Dec 2025 and grants stock options to executives and directors","bullets":["Rights Agreement amended to extend expiration to December 30, 2025.","Non-employee directors each granted options for 32,500 shares at $5.05, vesting Dec 5, 2026.","CEO Raymond Tesi granted options for 226,000 shares at $5.05, vesting Dec 5, 2026.","CFO David Moss granted 223,000 options; CSO Mark Lowdell 140,000 options, same terms.","All grants expire December 4, 2034 and were made under the 2021 Stock Incentive Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-106919","json":"https://secwatch.observer/filing/0001213900-24-106919.json","markdown":"https://secwatch.observer/filing/0001213900-24-106919.md","text":"https://secwatch.observer/filing/0001213900-24-106919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/0001213900-24-106919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/ea0223776-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:42:39.166530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}